Ranibizumab Prefilled Syringe Approved for Diabetic Retinopathy

Article

Diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 years in the US.

The FDA has approved ranibizumab injection 0.3 mg prefilled syringe (Lucentis) as a new method to administer the therapy to all forms of diabetic retinopathy (DR) in people with or without diabetic macular edema (DME).

The approval of the injection therapy from Genentech came April 2017, when it became the first and only FDA-approved therapy for all forms of DR in people with or without DME. The prefilled syringe options are now approved by the FDA for all use in all of Lucentis’ indications.

With the approval, the 0.3 mg prefilled syringe becomes the first syringe with anti-vascular endothelial growth factor (VEGF) agent approved by the FDA for use to treat DR and DME.

For more information, please visit MDMag.com.

Related Videos
Woman Physician Talking With Her Patient | Image Credit: LStockStudio - stock.adobe.com
A health visitor explaining a senior woman how to take pills - Image credit: Halfpoint | stock.adobe.com
Diabetes patient turn knob on end of insulin pen and dial up correct insulin dose for injection. Scale window on pen syringe showing number of units dose. Medical equipment is easy to self injection - Image credit: Orawan | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.